Introduction {#S1}
============

Gastrointestinal stromal tumors are rarely one of the gastrointestinal carcinomas that originate from mesenchymal tissue. GISTs are characterized by expression of CD117 receptor in cells and have variable biological phenotypes ranging from benign to highly malignant ([@B8]). As one of the most common non-epithelial neoplasms, they are mainly located in the stomach (55.6%) and small intestine (31.8%) ([@B18]). Radical surgery is the preferred treatment, and molecular target therapy, such as imatinib, can improve the survival of advanced patients with c-kit and/or PDGFRα mutations ([@B9]). However, a few effective tumor biomarkers are used for GIST diagnosis and prediction ([@B6]).

Circular RNA is a novel class of endogenous non-coding RNA characterized with 3′- and 5′-ends covalently linked in a closed-loop structure ([@B14]), which makes circRNAs resistant to exonucleases and more stable than traditional linear RNA, such as lncRNA and miRNA ([@B4]). Accordingly, the circRNAs can be divided into four types according to the source ([@B15]): exonic circRNAs (ecircRNA), intronic circRNA (ciRNA), exonic--intronic circRNA (EIciRNA), and intergenic circRNAs. Among them, 80% of circRNAs are ecircRNA. circRNAs may act as microRNA (miRNA/miR) sponges by competitively binding to miRNA response elements to influence downstream target gene expression, as well as affecting gene function at a post-translational level, and the same circRNA can regulate multiple miRNAs. Also, the same miRNAs can regulate multiple mRNA genes, thereby forming a large circRNA--miRNA--mRNA competitive network to affect the development of tumors ([@B21]). Also, some circRNAs can exert their activities via interaction with some proteins. Even then, some ecircRNAs may participate in the assembly and protein ribosomes translation. It was reported that circRNA is involved in various biological processes, including signal transduction and transcription, cell cycle regulation, RNA-binding protein, responses to stress, protein metabolism, cellular immunity, and cell structure ([@B11]). Recent studies ([@B13]; [@B3]) have also demonstrated that circRNA abnormal expression and regulation are involved in the occurrence and development of a variety of tumors. Therefore, circRNAs are of great importance as a biomarker for cancer diagnosis, cancer prediction, and treatment feedback, and may even serve as targets for cancer treatment.

In this study, we first analyzed the circRNA differential expression profile in GISTs using circRNA chip and identified six potential key circRNAs by qRT-PCR. Also, the circRNA--miRNA--mRNA network was constructed, and the GO and KEGG pathway were performed via bioinformatics analysis. Our study provides a novel insight into the molecular mechanisms of GISTs from the circRNA--miRNA--mRNA network view, and these circRNAs gave new direction for diagnosis and treatment of GISTs.

Materials and Methods {#S2}
=====================

Patients and Samples {#S2.SS1}
--------------------

Twenty pairs of GISTs and adjacent tissues were collected from The Second Xiangya Hospital of Central South University. All pathological specimens were experienced pathologists confirmed, did not accept the pre-operative radiotherapy, chemotherapy, and imatinib targeted therapy. The clinicopathological features are shown in [Table 1](#T1){ref-type="table"}. All tissues were collected during surgical operation and instantly stored in liquid nitrogen. The present project was permitted by the ethics committee of The Second Xiangya Hospital of Central South University, and informed consents were obtained from all the participants.

###### 

The clinicopathological features of GISTs patients.

  **Variables**              **Cases (*n*)**
  -------------------------- -----------------
  Total                      20
  **Age (years)**            
  ≥60                        12
  \<60                       8
  **Gender**                 
  Male                       15
  Female                     5
  **Tumor size (cm)**        
  ≤5                         9
  \>5                        11
  **Mitotic figure (HPF)**   
  ≤5/50                      13
  \>5/50                     7
  **Malignant degrees**      
  Low/Moderate risk          12
  High risk                  8

CircRNA Chip Detection {#S2.SS2}
----------------------

Total RNAs were extracted by RNeasy Mini Kit (Qiagen, Hilden, Germany). Total RNA from each sample was quantified using the NanoDrop ND-1000. The sample preparation and microarray hybridization were performed based on the Arraystar's standard protocols. Total RNAs were digested with Rnase R to remove linear RNAs and enrich CircRNAs. Then, the enriched CircRNAs were amplified and transcribed into fluorescent cRNA (Arraystar Super RNA Labeling Kit; Arraystar). The labeled cRNAs were hybridized onto the Arraystar Human circRNA Array V2 (8 × 15 K; Arraystar). Agilent Feature Extraction software (version 11.0.1.1) was used to analyze acquired array images. Quantile normalization and subsequent data processing were performed using the R software limma package. Differentially expressed circRNAs with statistical significance between two groups were identified through volcano plot filtering. Differentially expressed circRNAs between two samples were identified through fold change filtering. Hierarchical clustering was performed to show the distinguishable circRNA expression pattern among samples.

Quantitative Real-Time PCR {#S2.SS3}
--------------------------

Total RNAs were extracted using RNeasy Mini kit (Qiagen, Hilden, Germany). Then, RNA was reversed into complementary DNA (cDNA) by SuperScript III Reverse Transcriptase (Invitrogen). qRT-PCR was performed with 95.0°C for 3 min, and 39 circles of 95.0°C for 10 s and 60°C for 30 s using SYBR Green PCR Master Mix system. The relative expression levels were calculated using the 22^−ΔΔ*Ct*^ method. RNA levels were normalized to GAPDH expression. The forward (F) and reverse (R) primer sequences for qRT-PCR were designed and synthesized by Shanghai Kangcheng Co., Ltd. (Chinese).

CircRNA--miRNA--mRNA Interaction Prediction {#S2.SS4}
-------------------------------------------

The fundamental structure of circRNAs was predicted using Cancer-Specific circRNA (CSCD^[1](#footnote1){ref-type="fn"}^). circRNA--miRNA interactions were predicted using TargetScan and miRanda databases, and miRNA target gene was predicted using TargetScan, miRanda v5, and miBase prediction databases. Candidate miRNAs and mRNAs should be overlapped in at least two databases. Arraystar's miRNA target prediction software site: miRanda v5^[2](#footnote2){ref-type="fn"}^, TargetScan^[3](#footnote3){ref-type="fn"}^, and mibase^[4](#footnote4){ref-type="fn"}^. The circRNA--miRNA--mRNA competitive network (cirCeNET) was visualized by Cytoscape software (version 3.6.1^[5](#footnote5){ref-type="fn"}^).

Gene Ontology (GO) and KEGG Pathway Analysis {#S2.SS5}
--------------------------------------------

Gene ontology and KEGG pathways analysis was used to determine the function of candidate mRNAs in circRNA--miRNA--mRNA competitive network. DAVID^[6](#footnote6){ref-type="fn"}^ was used to predict the enriched functional categories and enriched signaling pathways. GO term, including BP, CC, MF, and KEGG pathway with *P* \< 0.05 and FDR \< 0.05 were considered as statistically significant.

Statistical Analysis {#S2.SS6}
--------------------

All data were analyzed by SPSS17.0 statistics software. Paired *t*-test was employed for the comparison of two groups. Chi-square test was used to investigate the relationship between circRNA expression and clinicopathologic features of GISTs patients. *P* \< 0.05 was considered as statistically significant.

Results {#S3}
=======

Differential CicrRNA Expression Profiles Were Established Successfully {#S3.SS1}
----------------------------------------------------------------------

The box plot showed similar distributions of tissues. In the volcano plots, differentially expressed circRNAs were categorized using fold change and *P* values. The scatter plots demonstrated the variation of differentially expressed circRNAs. Hierarchical cluster analysis showed differentially expressed circRNAs in GISTs with fold change \>1.5 and *P* \< 0.05 ([Figure 1A](#F1){ref-type="fig"}). After normalization and data analysis, compared with adjacent tissues, a total of 543 differentially expressed circRNAs were identified, including 242 up-regulated circRNAs and 301 down-regulated circRNAs, of which, exonic circRNAs accounted for 86.8% in up-regulated circRNAs and 87.4% in down-regulated circRNAs ([Figure 1B](#F1){ref-type="fig"}). The top 20 significantly up- and down-regulated circRNAs are listed in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}.

![Characterization of circRNA expression in GISTs. **(A)** Hierarchical cluster map. **(B)** The origin of upregulated and downregulated circRNAs. N, adjacent normal tissues; C, GIST tissues.](fgene-11-00403-g001){#F1}

###### 

Top 20 significantly up-regulated circRNAs.

  **circRNA**          ***P*-value**   **FDR**       **FC (abs)**   **Regulation**   **source**   **chrom**   **strand**   **type**            **GeneSymbol**
  -------------------- --------------- ------------- -------------- ---------------- ------------ ----------- ------------ ------------------- ----------------
  hsa_circRNA_061346   0.049017552     0.541205763   6.9877315      up               circBase     chr21       −            exonic              APP
  hsa_circRNA_103114   0.027813714     0.541205763   6.8848564      up               circBase     chr21       −            exonic              APP
  hsa_circRNA_103223   0.040961154     0.541205763   6.5339969      up               circBase     chr22       −            exonic              DDX17
  hsa_circRNA_100582   0.02164493      0.541205763   4.5762691      up               circBase     chr10       \+           exonic              ZEB1
  hsa_circRNA_001481   0.047719242     0.541205763   4.5058956      up               circBase     chr5        −            sense overlapping   EMB
  hsa_circRNA_103128   0.03858124      0.541205763   4.1057473      up               circBase     chr21       \+           exonic              DYRK1A
  hsa_circRNA_103870   0.039001555     0.541205763   4.0573338      up               circBase     chr5        \+           exonic              SMA4
  hsa_circRNA_404643   0.041732555     0.541205763   4.0082859      up               25070500     chr1        −            exonic              PIK3C2B
  hsa_circRNA_004182   0.039090826     0.541205763   3.428553       up               circBase     chr2        \+           intronic            CRIM1
  hsa_circRNA_103977   0.03760255      0.541205763   3.426974       up               circBase     chr5        \+           exonic              ARHGAP26
  hsa_circRNA_104076   0.047784401     0.541205763   3.2920026      up               circBase     chr6        −            exonic              KIF13A
  hsa_circRNA_101504   0.043980697     0.541205763   3.215775       up               circBase     chr15       \+           exonic              PDIA3
  hsa_circRNA_102510   0.029244589     0.541205763   3.1147657      up               circBase     chr19       \+           exonic              LSM14A
  hsa_circRNA_002164   0.048545781     0.541205763   3.082576       up               circBase     chr18       −            exonic              SS18
  hsa_circRNA_103224   0.006590126     0.541205763   3.0780956      up               circBase     chr22       −            exonic              DDX17
  hsa_circRNA_100915   0.030601002     0.541205763   3.0777302      up               circBase     chr11       −            exonic              PICALM
  hsa_circRNA_403471   0.003668259     0.541205763   3.060178       up               25242744     chr5        \+           exonic              ARHGAP26
  hsa_circRNA_102248   0.047545686     0.541205763   3.056733       up               circBase     chr17       \+           exonic              TBCD
  hsa_circRNA_404446   0.005776341     0.541205763   3.0361211      up               25070500     chr1        −            exonic              CAPZB
  hsa_circRNA_102378   0.045317666     0.541205763   2.9997955      up               circBase     chr18       \+           exonic              ZNF532

###### 

Top 20 significantly down-regulated circRNAs.

  **circRNA**          ***P*-value**   **FDR**       **FC (abs)**   **Regulation**   **source**   **chrom**   **strand**   **type**            **GeneSymbol**
  -------------------- --------------- ------------- -------------- ---------------- ------------ ----------- ------------ ------------------- ----------------
  hsa_circRNA_405324   0.013412911     0.541205763   4.3231649      down             25070500     chr15       \+           sense overlapping   STARD9
  hsa_circRNA_405443   0.028911656     0.541205763   3.3381633      down             25070500     chr16       \+           intronic            NDE1
  hsa_circRNA_406309   0.01797211      0.541205763   3.1653952      down             25070500     chr3        \+           intronic            CMSS1
  hsa_circRNA_100075   0.029545308     0.541205763   3.1382274      down             circBase     chr1        −            exonic              EMC1
  hsa_circRNA_406821   0.020949363     0.541205763   3.0380172      down             25070500     chr6        \+           exonic              ARMC2
  hsa_circRNA_000361   0.027240076     0.541205763   3.0118108      down             circBase     chr3        −            antisense           PLCL2
  hsa_circRNA_082335   0.035559522     0.541205763   3.008493       down             circBase     chr7        \+           exonic              KLHDC10
  hsa_circRNA_102207   0.013654637     0.541205763   3.0013356      down             circBase     chr17       \+           exonic              AFMID
  hsa_circRNA_405825   0.015220854     0.541205763   2.522762       down             25070500     chr2        \+           exonic              KLF11
  hsa_circRNA_074660   0.017052344     0.541205763   2.4763773      down             circBase     chr5        −            exonic              ATOX1
  hsa_circRNA_104924   0.01941688      0.541205763   2.4549169      down             circBase     chr9        \+           exonic              MVB12B
  hsa_circRNA_056037   0.027008503     0.541205763   2.4478589      down             circBase     chr2        −            exonic              BUB1
  hsa_circRNA_406780   0.028354789     0.541205763   2.3707217      down             25070500     chr6        −            sense overlapping   DNPH1
  hsa_circRNA_024371   0.025742814     0.541205763   2.36132        down             circBase     chr11       \+           exonic              PAFAH1B2
  hsa_circRNA_061284   0.026417014     0.541205763   2.30245        down             circBase     chr21       \+           exonic              USP25
  hsa_circRNA_100456   0.009103973     0.541205763   2.2394652      down             circBase     chr1        \+           exonic              KCNK2
  hsa_circRNA_083919   0.037676327     0.541205763   2.213904       down             circBase     chr8        \+           exonic              UNC5D
  hsa_circRNA_406295   0.017374416     0.541205763   2.2027287      down             25070500     chr3        \+           sense overlapping   SUCLG2-AS1
  hsa_circRNA_035426   0.040284453     0.541205763   2.2016635      down             circBase     chr15       \+           exonic              TCF12
  hsa_circRNA_405296   0.023543643     0.541205763   2.1972163      down             25070500     chr15       \+           sense overlapping   TUBGCP5

qRT-PCR Validation {#S3.SS2}
------------------

The top eight most upregulated circRNAs with fold change \>4 and *P* \< 0.05 and the top eight most downregulated circRNAs with fold change \>3 and *P* \< 0.05 are shown in the cluster heat map ([Figure 2A](#F2){ref-type="fig"}). qRT-PCR assay was used to assess the accuracy of circRNAs chip data. After filtering circRNAs with low raw intensity, six candidate circRNAs, including three up-regulated circRNAs (hsa\_ circRNA_061346, hsa_circRNA_103114, hsa_circRNA_103870) and three down-regulated circRNAs (hsa_circRNA_405324, hsa_circRNA_406821, hsa_circRNA\_ 000361) were selected for qRT-PCR analysis. The results showed that qRT-PCR results were consistent with the circRNAs chip data ([Figure 2B](#F2){ref-type="fig"}), indicating the reliability of circRNAs chip data.

![qRT-PCR validation. **(A)** The cluster heat map of the top eight most up-regulated and down-regulated circRNAs. **(B)** Comparison of Arraystar human circRNAs chip data and qRT-PCR results. circRNAs expression levels were normalized to GAPDH. N, adjacent normal tissues; C, GIST tissues.](fgene-11-00403-g002){#F2}

CircRNA--miRNA--mRNA Network Construction {#S3.SS3}
-----------------------------------------

The fundamental structure modes of the six candidate circRNAs predicted by CSCD are shown in [Figure 3](#F3){ref-type="fig"}. To estimate the function of six candidate circRNAs, circRNA--miRNA interactions were constructed with TargetScan and miRanda databases. The top five targeted miRNAs of six candidate circRNAs are exhibited in [Figure 4](#F4){ref-type="fig"}, and the detailed potential circRNA--miRNA interaction sites of targeted miRNAs with the highest context score percentile are shown in [Figure 5](#F5){ref-type="fig"}. Then, the circRNA--miRNA--mRNA competitive network (cirCeNET) was visualized by Cytoscape software (version 3.6.1) based on circRNA--miRNA interactions and miRNA--mRNA interactions ([Figure 6](#F6){ref-type="fig"}). This network contained six circRNAs, 30 miRNAs, and 308 mRNAs, which provided a comprehensive perspective into the links between circRNA, miRNA, and mRNAs in GISTs.

![The fundamental structure modes of the six candidate circRNAs predicted by CSCD. **(A)** Up-regulated circRNAs: hsa_circRNA_061346, hsa_circRNA_103114, hsa_circRNA_103870. **(B)** Down-regulated circRNAs: hsa_circRNA_405324, hsa\_ circRNA \_406821, hsa_circRNA_000361.](fgene-11-00403-g003){#F3}

![circRNA--miRNA regulatory network. **(A)** The top five targeted miRNAs of up-regulated circRNAs. **(B)** The top five targeted miRNAs of down-regulated circRNAs.](fgene-11-00403-g004){#F4}

![The detailed potential circRNA--miRNA interaction sites of targeted miRNAs with highest context score percentile based on TargetScan and miRanda data.](fgene-11-00403-g005){#F5}

![circRNA--miRNA--mRNA regulatory network. Up-regulated circRNAs, down-regulated circRNAs, miRNA, and mRNA are presented as square, hexagon, diamond, and circle, respectively.](fgene-11-00403-g006){#F6}

GO and KEGG Pathway Analysis {#S3.SS4}
----------------------------

The GO analysis demonstrated that the term with the highest enrichment score was regulation of biological process (GO:0050789) for biological process terms (BP), intracellular organelle (GO:0043229) for cellular component terms (CC), and protein binding (GO:0005515) for molecular function terms (MF), respectively. The top 10 enrichment scores are shown in [Figures 7A--C](#F7){ref-type="fig"}. The KEGG pathway with the highest enrichment score was the Wnt signaling pathway. The top 10 enriched KEGG pathways are shown in [Figure 7D](#F7){ref-type="fig"}.

![GO and KEGG pathway analysis. **(A--C)** GO annotation of targeted mRNAs with the top 10 enrichment scores for biological process, cellular component, and molecular function, respectively. **(D)** The top 10 enriched KEGG pathways. GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.](fgene-11-00403-g007){#F7}

qRT-PCR Validation {#S3.SS5}
------------------

Six significantly differential circRNAs were also verified in 20 pairs of GISTs and adjacent tissues by qRT-PCR. The results showed that circRNA_061346, circRNA_103114, and circRNA_103870 were significantly up-regulated in GIST tissues ([Figure 8](#F8){ref-type="fig"}) (*P* \< 0.05), and circRNA_405324, circRNA\_ 406821, and circRNA_000361 were dramatically down-regulated in GIST tissues ([Figure 9](#F9){ref-type="fig"}) *P* \< 0.05), compared with corresponding adjacent tissues.

![The relative expression of up-regulated circRNAs of 20 GIST tissues were detected by qRT-PCR, **(A)** hsa_circRNA_061346; **(B)** hsa_circRNA_103114; **(C)** hsa\_ circRNA_103870. circRNA expression levels were normalized to GAPDH.](fgene-11-00403-g008){#F8}

![The relative expression of down-regulated circRNAs of 20 GIST tissues was detected by qRT-PCR, **(A)** hsa_circRNA_405324; **(B)** hsa_circRNA \_406821; **(C)** hsa_circRNA_000361. circRNA expression levels were normalized to GAPDH.](fgene-11-00403-g009){#F9}

Diagnosis Values of CircRNA {#S3.SS6}
---------------------------

In order to determine the diagnostic value of six candidate circRNAs in GISTs, the ROC curve was employed. Statistical analysis demonstrated that all six candidate circRNAs had high diagnostic efficiency with AUC = 0.9925, AUC = 0.9824, AUC = 0.9231, AUC = 0.9300, AUC = 0.9463, AUC = 0.9138 for circRNA_061346, circRNA_103114, circRNA_103870 and circRNA_405324, circRNA_406821, circRNA_000361, respectively ([Figure 10](#F10){ref-type="fig"}) (*P* \< 0.05).

![The diagnostic value of six candidate circRNAs in GISTs. **(A)** ROC curve for three up-regulated circRNAs. **(B)** ROC curve for three down- regulated circRNAs.](fgene-11-00403-g010){#F10}

Correlation of CircRNA Expressions With Clinical Pathologic Features {#S3.SS7}
--------------------------------------------------------------------

In order to investigate the correlation of six candidate circRNA expressions with clinical--pathologic features, the median circRNA expression was used to divide the 20 pairs of GISTs tissues into higher and lower circRNA expression groups. Chi-square assay was employed for statistical analysis. The results suggested that circRNA_061346 and circRNA_103114 expressions were positively associated with tumor size, mitotic figure, malignant degrees, and circRNA_103870 expression was positively associated with tumor size, mitotic figure, but without relation to malignant degrees ([Figure 11](#F11){ref-type="fig"}). On the contrary, circRNA_405324 expression was negatively associated with tumor size, mitotic figure, malignant degrees, and circRNA_406821 was negatively correlated with mitotic figure, malignant degrees, but not with tumor size; nevertheless, circRNA_000361 expression was only negatively related with mitotic figure ([Figure 11B](#F11){ref-type="fig"}). However, there was no correlation with age, gender, and tumor location.

![Correlation of six candidate circRNAs with clinical pathologic features. **(A)** Box plots for three up-regulated circRNAs. **(B)** Box plots for three down-regulated circRNAs. Tumor size: ≤5 cm, \>5 cm; mitotic figure: ≤5/50 HPF, \<5/50 HPF; malignant degrees: low risk, moderate risk, high risk.](fgene-11-00403-g011){#F11}

Discussion {#S4}
==========

Gastrointestinal stromal tumors are a rare malignant tumor that occurs principally in the stomach, small intestine, and colon--rectum ([@B7]). K-ras gene mutation might be correlated with the mechanism of development and infiltration of GISTs, but the pathogenesis of GISTs is inadequately understood ([@B12]). A growing body of research ([@B19]; [@B1]; [@B23]) demonstrates that the development of cancer is often accompanied by abnormal expression of circRNA. Also, circRNA is characterized by inherent stability, highly conservative, and universality. Therefore, circRNA is of great importance as a biomarker for cancer screening, cancer diagnosis, cancer prediction, feedback of treatment, and prognosis. Additionally, circRNA's abnormal expression and the circRNA--miRNA--mRNA regulatory network regulation have been increasingly demonstrated in a variety of tumors, such as circRNA_CAMK2A--miR-615-5p--fibronectin 1 network in lung adenocarcinoma metastasis ([@B5]), circRNA_0006948--miR-490-3p--HMGA2 network in esophageal squamous cell carcinoma ([@B16]), circRNA_ACAP2--miR-29a/b-3p--COL5A1 network in breast cancer ([@B25]), circRNA_51217--miRNA-646--TGFβ1/p-Smad2/3 network in prostate cancer ([@B20]), etc. At present, there are few reports about the circRNA--miRNA--mRNA regulatory network in GISTs.

In the present study, we illuminate the molecular mechanisms of circRNAs in the occurrence and development of GISTs for the first time. We first performed circRNA chip analysis to assess differential cicrRNA expression profiles in GIST tissues and corresponding non-cancer tissues. A totally of 543 differentially expressed circRNAs were identified, of which 242 were significantly upregulated and 301 were significantly downregulated in GISTs tissues. Additionally, in order to fully elucidated the function of the circRNA-related ceRNA in GISTs, six candidate circRNAs including three up-regulated circRNAs (hsa_circRNA_061346, hsa_circRNA_103114, hsa\_ circRNA_103870) and three down-regulated circRNAs (hsa_circRNA_405324, hsa\_ circRNA_406821, hsa_circRNA_000361) were identified to be involved in the ceRNA network. The ceRNA network consists of six circRNAs, 30 miRNAs, and 308 mRNAs. In this network, previous studies ([@B22]; [@B24]) show that many miRNAs, such as miR-4778-3p, miR-147b, miR-1182, and miR-378a-3p, were involved in tumor cell growth, invasion, and metastasis. Also, many targeted genes, such as ZEB1, SOX5, AKAP1, CHP1, CNBP, VEGFR, and MAGT1, play a vital function in the cell shape, movement, invasion, adhesion, and polarity formation, so as to involve in many kinds of diseases such as malignant tumors, wound healing, and so on ([@B17]; [@B2]; [@B10]).

Furthermore, 20 GIST tissues and adjacent tissues were collected to verify the expression of identified six candidate circRNAs. qRT-PCR results showed that hsa_circRNA_061346, hsa_circRNA_103114, and hsa_circRNA_103870 were significantly up-regulated in GISTs, and hsa\_ circRNA_405324, hsa_circRNA \_406821, hsa_circRNA\_ 000361 were dramatically down-regulated in GISTs. In addition, all of these circRNAs were shown to have high diagnostic values, and most of them were significantly associated with tumor size, mitotic figure, and malignant degrees in GISTs. The six candidate circRNAs might be critical circRNAs participating in the occurrence and development of GISTs and can serve as novel potential diagnostic biomarkers for GISTs patients. Through a large literature review, very limited data are available about these circRNAs's functions and their deregulation in cancer.

However, there are several limitations to our study. First, only 20 patients were enrolled in our study, the sample size is relatively small, and the result showed an association, rather than a definite, causal relationship. Also, the relation analysis of clinical factors and circRNAs needs to be supported by large samples. Second, in our study, we only conducted a network based on identified six critical circRNAs, miRNA, and target mRNA, but a total of 543 circRNAs were identified in GISTs. Other circRNAs may contribute as well. Third, our paper starts with a general analysis of circRNAs in GISTs, but the mechanism is not discussed in detail. Therefore, in our future work, further studies with larger groups of patients, a network based on 543 circRNAs are needed to confirm these findings, and the concrete mechanism of circRNAs in GISTs also needs to be further explored.

Conclusion {#S5}
==========

In the present study, the differential circRNA expression profile of GISTs was established, and a total of 543 differentially expressed circRNAs were screened. In addition, the circRNA--miRNA--mRNA regulatory network was constructed. hsa_circRNA\_ 061346, hsa_circRNA_103114, hsa_circRNA_103870 and hsa_circRNA_405324, hsa\_ circRNA_406821, hsa_circRNA_000361 were identified as critical circRNAs in the occurrence and development of GISTs and may present as potential diagnostic biomarkers for GISTs. In brief, our study provides a new insight into the pathogenesis of GISTs from the circRNA--miRNA--mRNA regulatory network view.
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